{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:15:36Z","timestamp":1783937736222,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T00:00:00Z","timestamp":1288742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/npp.2010.195","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T11:05:38Z","timestamp":1288782338000},"page":"638-651","source":"Crossref","is-referenced-by-count":60,"title":["The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy"],"prefix":"10.1038","volume":"36","author":[{"given":"Prem N","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheir I","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martilias S","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Setola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Sciaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley K","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaTasha K","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Piel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"Shoichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S","family":"Deneris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Gingrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl G","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan L","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,3]]},"reference":[{"key":"BFnpp2010195_CR1","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1523\/JNEUROSCI.1090-09.2009","volume":"29","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG et al (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29: 7124\u20137136.","journal-title":"J Neurosci"},{"key":"BFnpp2010195_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1055\/s-0028-1094312","volume":"4","author":"J Angst","year":"1971","unstructured":"Angst J, Jaenicke U, Padrutt A, Scharfetter C (1971). Ergebnisse eines Doppelblindversuches von HF 1854* (8-Chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b, e) (1,4) diazepin) im Vergleich zu Levomepromazin. Pharmacopsychiatry 4: 192\u2013200.","journal-title":"Pharmacopsychiatry"},{"key":"BFnpp2010195_CR3","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1074\/jbc.R400030200","volume":"280","author":"BN Armbruster","year":"2005","unstructured":"Armbruster BN, Roth BL (2005). Mining the receptorome. J Biol Chem 280: 5129\u20135132.","journal-title":"J Biol Chem"},{"key":"BFnpp2010195_CR4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0022-3565(25)23831-9","volume":"271","author":"VP Bakshi","year":"1994","unstructured":"Bakshi VP, Swerdlow NR, Geyer MA (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271: 787\u2013794.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010195_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1146\/annurev.pharmtox.011008.145634","volume":"49","author":"JM Beaulieu","year":"2009","unstructured":"Beaulieu JM, Gainetdinov RR, Caron MG (2009). Akt\/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49: 327\u2013347.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFnpp2010195_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cell.2007.11.041","volume":"132","author":"JM Beaulieu","year":"2008","unstructured":"Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V et al (2008). A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125\u2013136.","journal-title":"Cell"},{"key":"BFnpp2010195_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.cell.2005.05.012","volume":"122","author":"JM Beaulieu","year":"2005","unstructured":"Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005). An Akt\/beta-arrestin 2\/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261\u2013273.","journal-title":"Cell"},{"key":"BFnpp2010195_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1152\/jn.00744.2003","volume":"91","author":"SG Beck","year":"2004","unstructured":"Beck SG, Pan YZ, Akanwa AC, Kirby LG (2004). Median and dorsal raphe neurons are not electrophysiologically identical. J Neurophysiol 91: 994\u20131005.","journal-title":"J Neurophysiol"},{"key":"BFnpp2010195_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nn.2447","volume":"13","author":"JE Belforte","year":"2010","unstructured":"Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y et al (2010). Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13: 76.","journal-title":"Nat Neurosci"},{"key":"BFnpp2010195_CR10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0022-3565(25)11335-9","volume":"260","author":"C Bolden","year":"1992","unstructured":"Bolden C, Cusack B, Richelson E (1992). Antagonism by anitmuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharm Exp Ther 260: 576\u2013580.","journal-title":"J Pharm Exp Ther"},{"key":"BFnpp2010195_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.biopsych.2005.03.016","volume":"58","author":"RA Bressan","year":"2005","unstructured":"Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ et al (2005). Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol Psychiatry 58: 41\u201346.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 4","key":"BFnpp2010195_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/PL00014183","volume":"249","author":"A Carlsson","year":"1999","unstructured":"Carlsson A, Waters N, Carlsson ML (1999). Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiatry Clin Neurosci 249 (Suppl 4): 37\u201343.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BFnpp2010195_CR13","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/sj.npp.1301638","volume":"33","author":"PJ Conn","year":"2008","unstructured":"Conn PJ, Roth BL (2008). Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33: 2048\u20132060.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2010195_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481\u2013483.","journal-title":"Science"},{"key":"BFnpp2010195_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/263338a0","volume":"263","author":"SJ Enna","year":"1976","unstructured":"Enna SJ, Bennett Jr JP, Burt DR, Creese I, Snyder SH (1976). Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature 263: 338\u2013341.","journal-title":"Nature"},{"key":"BFnpp2010195_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0091-3057(84)90297-1","volume":"20","author":"H Fink","year":"1984","unstructured":"Fink H, Morgenstern R, Oelssner W (1984). Clozapine\u2014a serotonin antagonist? Phamacol Biochem Behav 20: 513\u2013517.","journal-title":"Phamacol Biochem Behav"},{"key":"BFnpp2010195_CR17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/13.4.643","volume":"13","author":"MA Geyer","year":"1987","unstructured":"Geyer MA, Braff DL (1987). Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 13: 643\u2013668.","journal-title":"Schizophr Bull"},{"key":"BFnpp2010195_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/sj.mp.4002062","volume":"12","author":"JA Gray","year":"2007","unstructured":"Gray JA, Roth BL (2007). The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12: 904.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2010195_CR19","doi-asserted-by":"publisher","first-page":"10348","DOI":"10.1523\/JNEUROSCI.19-23-10348.1999","volume":"19","author":"T Hendricks","year":"1999","unstructured":"Hendricks T, Francis N, Fyodorov D, Deneris ES (1999). The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. J Neurosci 19: 10348\u201310356.","journal-title":"J Neurosci"},{"key":"BFnpp2010195_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0896-6273(02)01167-4","volume":"37","author":"TJ Hendricks","year":"2003","unstructured":"Hendricks TJ, Fyodorov DV, Wegman LJ, Lelutiu NB, Pehek EA, Yamamoto B et al (2003). Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron 37: 233\u2013247.","journal-title":"Neuron"},{"key":"BFnpp2010195_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1021\/ci8000259","volume":"48","author":"J Hert","year":"2008","unstructured":"Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK (2008). Quantifying the relationships among drug classes. J Chem Inf Model 48: 755\u2013765.","journal-title":"J Chem Inf Model"},{"issue":"Suppl 12","key":"BFnpp2010195_CR22","first-page":"22","volume":"60","author":"H Hippius","year":"1999","unstructured":"Hippius H (1999). A historical perspective of clozapine. J Clin Psychiatry 60 (Suppl 12): 22\u201323.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2010195_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins AL, Groom CR (2002). The druggable genome. Nat Rev Drug Discov 1: 727\u2013730.","journal-title":"Nat Rev Drug Discov"},{"key":"BFnpp2010195_CR24","volume-title":"Daylight Theory Manual","author":"CA James","year":"1992","unstructured":"James CA, Weininger D, Delaney J (1992). Daylight Theory Manual. Daylight Chemical Information Systems, Inc.: Mission Viejo, CA."},{"key":"BFnpp2010195_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.mp.4001552","volume":"10","author":"DC Javitt","year":"2005","unstructured":"Javitt DC, Duncan L, Balla A, Sershen H (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry 10: 275\u2013287.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2010195_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301\u20131308.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2010195_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nn2050","volume":"11","author":"P Jensen","year":"2008","unstructured":"Jensen P, Farago AF, Awatramani RB, Scott MM, Deneris ES, Dymecki SM (2008). Redefining the serotonergic system by genetic lineage. Nat Neurosci 11: 417\u2013419.","journal-title":"Nat Neurosci"},{"key":"BFnpp2010195_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfield G, Singer J, Meltzer HY (1988). Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789\u2013796.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2010195_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158: 360\u2013369.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2010195_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.tips.2010.05.004","volume":"31","author":"CS Karam","year":"2010","unstructured":"Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE et al (2010). Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 31: 381\u2013390.","journal-title":"Trends Pharmacol Sci"},{"key":"BFnpp2010195_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nbt1284","volume":"25","author":"MJ Keiser","year":"2007","unstructured":"Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK (2007). Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197\u2013206.","journal-title":"Nat Biotechnol"},{"key":"BFnpp2010195_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature08506","volume":"462","author":"MJ Keiser","year":"2009","unstructured":"Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ et al (2009). Predicting new molecular targets for known drugs. Nature 462: 175\u2013181.","journal-title":"Nature"},{"key":"BFnpp2010195_CR33","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.109.155663","volume":"330","author":"Z Li","year":"2009","unstructured":"Li Z, Prus AJ, Dai J, Meltzer HY (2009). Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther 330: 948\u2013955.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010195_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209\u20131223.","journal-title":"N Engl J Med"},{"key":"BFnpp2010195_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hup.403","volume":"17","author":"K Linnet","year":"2002","unstructured":"Linnet K (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 17: 233\u2013238.","journal-title":"Hum Psychopharmacol"},{"key":"BFnpp2010195_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nn.2529","volume":"13","author":"AC Magalhaes","year":"2010","unstructured":"Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN et al (2010). CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13: 622\u2013629.","journal-title":"Nat Neurosci"},{"key":"BFnpp2010195_CR37","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002). The protein kinase complement of the human genome. Science 298: 1912\u20131934.","journal-title":"Science"},{"key":"BFnpp2010195_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0893-133X(89)90035-3","volume":"2","author":"RS Mansbach","year":"1989","unstructured":"Mansbach RS, Geyer MA (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2: 299\u2013308.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2010195_CR39","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1126\/science.282.5395.1893","volume":"282","author":"S Matsuoka","year":"1998","unstructured":"Matsuoka S, Huang M, Elledge SJ (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893\u20131897.","journal-title":"Science"},{"key":"BFnpp2010195_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60: 82\u201391.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2010195_CR41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee J-C (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238\u2013246.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010195_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1176\/ajp.152.1.153","volume":"152","author":"HY Meltzer","year":"1995","unstructured":"Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183\u2013190.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2010195_CR43","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/248596a0","volume":"248","author":"RJ Miller","year":"1974","unstructured":"Miller RJ, Hiley CR (1974). Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature (London) 248: 546\u2013547.","journal-title":"Nature (London)"},{"key":"BFnpp2010195_CR44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","volume":"98","author":"AR Mohn","year":"1999","unstructured":"Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427\u2013436.","journal-title":"Cell"},{"key":"BFnpp2010195_CR45","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0014-2999(88)90544-4","volume":"151","author":"JF Nash","year":"1988","unstructured":"Nash JF, Meltzer HY, Gudelsky GA (1988). Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 151: 463\u2013469.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2010195_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","volume":"355","author":"A Newman-Tancredi","year":"1998","unstructured":"Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L et al (1998). Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355: 245\u2013256.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2010195_CR47","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10822-004-4060-8","volume":"18","author":"M Olah","year":"2004","unstructured":"Olah M, Bologa C, Oprea TI (2004). An automated PLS search for biologically relevant QSAR descriptors. J Comput Aided Mol Des 18: 437\u2013449.","journal-title":"J Comput Aided Mol Des"},{"key":"BFnpp2010195_CR48","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nchembio0807-447","volume":"3","author":"TI Oprea","year":"2007","unstructured":"Oprea TI, Tropsha A, Faulon JL, Rintoul MD (2007). Systems chemical biology. Nat Chem Biol 3: 447\u2013450.","journal-title":"Nat Chem Biol"},{"key":"BFnpp2010195_CR49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.7221567","volume":"212","author":"SJ Peroutka","year":"1981","unstructured":"Peroutka SJ, Lebovitz RM, Snyder SH (1981). Two distinct serotonin receptors with distinct physiological functions. Science 212: 827\u2013829.","journal-title":"Science"},{"key":"BFnpp2010195_CR50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","volume":"460","author":"SM Purcell","year":"2009","unstructured":"Purcell SM, Wray NR, Stone JL, Visscher PM, O\u2019Donovan MC, Sullivan PF et al (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 748\u2013752.","journal-title":"Nature"},{"key":"BFnpp2010195_CR51","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1016\/S0014-2999(97)81951-6","volume":"338","author":"H Rollema","year":"1997","unstructured":"Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338: R3\u2013R5.","journal-title":"Eur J Pharmacol"},{"key":"BFnpp2010195_CR52","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0022-3565(25)11452-3","volume":"260","author":"BL Roth","year":"1992","unstructured":"Roth BL, Ciaranello RD, Meltzer HY (1992). Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260: 1361\u20131365.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010195_CR53","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"BL Roth","year":"1994","unstructured":"Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr FJ, Shen Y et al (1994). Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403\u20131410.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010195_CR54","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353\u2013359.","journal-title":"Nat Rev Drug Discov"},{"key":"BFnpp2010195_CR55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","volume":"280","author":"H Schoemaker","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280: 83\u201397.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2010195_CR56","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.lfs.2008.05.014","volume":"83","author":"L Schwieler","year":"2008","unstructured":"Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G (2008). Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci 83: 170\u2013175.","journal-title":"Life Sci"},{"key":"BFnpp2010195_CR57","doi-asserted-by":"publisher","first-page":"16472","DOI":"10.1073\/pnas.0504510102","volume":"102","author":"MM Scott","year":"2005","unstructured":"Scott MM, Wylie CJ, Lerch JK, Murphy R, Lobur K, Herlitze S et al (2005). A genetic approach to access serotonin neurons for in vivo and in vitro studies. Proc Natl Acad Sci USA 102: 16472\u201316477.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2010195_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","volume":"16","author":"P Seeman","year":"1997","unstructured":"Seeman P, Corbett R, Van Tol HH (1997). Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16: 93\u2013110, discussion 111\u2013135.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2010195_CR59","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(77)91410-6","volume":"1","author":"HJ Senn","year":"1977","unstructured":"Senn HJ, Jungi WF, Kunz H, Poldinger W (1977). Clozapine and agranulocytosis. Lancet 1: 547.","journal-title":"Lancet"},{"key":"BFnpp2010195_CR60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nature08192","volume":"460","author":"J Shi","year":"2009","unstructured":"Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe\u2032er I et al (2009). Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460: 753\u2013757.","journal-title":"Nature"},{"key":"BFnpp2010195_CR61","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","volume":"460","author":"H Stefansson","year":"2009","unstructured":"Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al (2009). Common variants conferring risk of schizophrenia. Nature 460: 744\u2013747.","journal-title":"Nature"},{"key":"BFnpp2010195_CR62","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature07229","volume":"455","author":"H Stefansson","year":"2008","unstructured":"Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S et al (2008). Large recurrent microdeletions associated with schizophrenia. Nature 455: 232\u2013236.","journal-title":"Nature"},{"key":"BFnpp2010195_CR63","doi-asserted-by":"publisher","first-page":"13674","DOI":"10.1073\/pnas.1835612100","volume":"100","author":"C Sur","year":"2003","unstructured":"Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100: 13674\u201313679.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2010195_CR64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"HH Van Tol","year":"1991","unstructured":"Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610\u2013614.","journal-title":"Nature"},{"key":"BFnpp2010195_CR65","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1124\/jpet.104.080200","volume":"313","author":"M Wittmann","year":"2005","unstructured":"Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ (2005). Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A\/Src kinases. J Pharmacol Exp Ther 313: 594\u2013603.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2010195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2010195","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2010195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:20:33Z","timestamp":1740651633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2010195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["BFnpp2010195"],"URL":"https:\/\/doi.org\/10.1038\/npp.2010.195","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.6134956.6172054","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,3]]}}}